Unknown

Dataset Information

0

Plerixafor for autologous CD34 cell mobilization.


ABSTRACT: High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34(+) cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

SUBMITTER: Salman H 

PROVIDER: S-EPMC3065558 | BioStudies | 2011-01-01T00:00:00Z

SECONDARY ACCESSION(S): NCT00906945

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4215600 | BioStudies
2015-01-01 | S-EPMC4512229 | BioStudies
2013-01-01 | S-EPMC3787462 | BioStudies
2013-01-01 | S-EPMC3892143 | BioStudies
2009-01-01 | S-EPMC2746476 | BioStudies
2016-01-01 | S-EPMC4806642 | BioStudies
2013-01-01 | S-EPMC3865534 | BioStudies
2012-01-01 | S-EPMC3255592 | BioStudies
2019-01-01 | S-EPMC6436017 | BioStudies
1000-01-01 | S-EPMC3804935 | BioStudies